home / stock / pbm / pbm news


PBM News and Press, Psyence Biomedical Ltd. From 09/18/25

Stock Information

Company Name: Psyence Biomedical Ltd.
Stock Symbol: PBM
Market: NASDAQ
Website: www.psyencebiomed.com

Menu

PBM PBM Quote PBM Short PBM News PBM Articles PBM Message Board
Get PBM Alerts

News, Short Squeeze, Breakout and More Instantly...

PBM - US Companies Moving the Markets, Evening edition
Thu, Sep 18, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Adaptimmune Therapeutics plc (ADAP) rose 98.0% to $0.16 on volume of 728,354,687 shares Intel Corporation (INTC) rose 22.8% to $30.57 on volume of 520,197,517 shares Datavault AI Inc. (DVLT) rose 21.0% to $0.4147 on volume of 294,006,45...

PBM - US Companies Moving the Markets, Morning edition
Thu, Sep 18, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States Datavault AI Inc. (DVLT) rose 31.7% to $0.45145 on volume of 160,605,677 shares Intel Corporation (INTC) rose 24.7% to $31.06 on volume of 160,224,243 shares Aptevo Therapeutics Inc. (APVO) rose 67.7% to $2.365 on volume of 66,397,378 s...

PBM - Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that it will pre...

PBM - US Companies Moving the Markets, Evening edition
Mon, Aug 04, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Opendoor Technologies Inc (OPEN) rose 17.1% to $2.46 on volume of 264,409,281 shares AtlasClear Holdings Inc. (ATCH) rose 39.5% to $0.2216 on volume of 218,466,534 shares NVIDIA Corporation (NVDA) rose 3.6% to $180 on volume of 145,593,...

PBM - PRISM Mid-Day Movers: Psychedelic Surge and Strategic Sales Boost Indices

2025-08-04 14:31:22 ET Psyence BioMed Skyrockets 74% on Expanded Trial Access and Strategic Momentum Psyence BioMed ( PBM ) soared 74.15% to lead the PRISM Emerging Psychedelics Index after announcing multiple clinical, regulatory, and operational advances . The company re...

PBM - Trade These, Not Those: Capital Rotation in Motion as Blade, Kraig, Psyence, and Verb Redefine the Small-Cap Narrative

2025-08-04 10:22:45 ET DENVER, Colo., Aug 04, 2025 ( 247marketnews.com )- In a market still dominated by rate headlines and ETF-driven flows, the most interesting money is chasing transformation. Trade These: Joby (NYSE:JOBY) and Blade Air Mobility (NASDAQ:BLDE) Blade just h...

PBM - US Companies Moving the Markets, Morning edition
Mon, Aug 04, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States AtlasClear Holdings Inc. (ATCH) rose 37.7% to $0.2187 on volume of 122,410,058 shares Oriental Rise Holdings Limited (ORIS) rose 15.3% to $0.1266 on volume of 91,052,874 shares Opendoor Technologies Inc (OPEN) rose 8.5% to $2.279 on vol...

PBM - Corporate Update, August 2025

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and naturally derived psychedelic therapies for people living with ser...

PBM - US Companies Moving the Markets, Evening edition
Fri, Aug 01, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Erayak Power Solution Group Inc. (RAYA) rose 41.4% to $0.084 on volume of 564,200,836 shares LOBO EV TECHNOLOGIES LTD. (LOBO) rose 118.7% to $0.7864 on volume of 419,806,285 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose...

PBM - PRISM Mid-Day Movers: Mental Health Momentum and Biotech Setbacks Define Market Sentiment

2025-08-01 13:01:29 ET BioXcel Rallies 27% on Expanded Schizophrenia Study and Positive FDA Interaction BioXcel Therapeutics, Inc. ( BTAI ) surged 27.48% to lead the PRISM Emerging Mental Health Index after announcing a pivotal update to its TRANQUILITY III trial evaluating ...

Previous 10 Next 10